Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-08-23
2005-08-23
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007910, C435S006120, C435S005000, C435S007940
Reexamination Certificate
active
06933123
ABSTRACT:
An isolated protein sequence or peptide from the E2, E6 or E7 early coding region of human papillomavirus (HPV) that is soluble in an aqueous medium, and characterized by a relative paucity of tryptophan, methionine and cysteine residues, and a relative abundance of glycine and asparagine residues. Also disclosed are isolated protein sequences or peptides from the E2, E6 or E7 early coding regions of HPV 16 and 18 and methodologies for detecting or diagnosing cancer or cellular abnormalities. Detection or diagnosis of Cancer or cellular abnormalities may include detecting or diagnosing pre-cancerous or pre-malignant conditions, cervical dysplasia, cervical carcinoma, koilocytosis, hyperkeratosis, intraepithelial lesions, and other cancers. A methodology for detecting or diagnosing cancer or cellular abnormalities comprises the steps of (1) reacting a sample of body fluid or tissue with isolated protein sequences or peptides; (2) forming an antibody-peptide complex; and (3) detecting the antibody-peptide complex.
REFERENCES:
patent: 4777239 (1988-10-01), Schoolnik et al.
patent: 5629146 (1997-05-01), Dillner et al.
patent: 5629161 (1997-05-01), Muller et al.
patent: 5679509 (1997-10-01), Wheeler et al.
patent: 5753233 (1998-05-01), Bleul et al.
patent: 5932412 (1999-08-01), Dillner et al.
patent: 6096869 (2000-08-01), Stanley et al.
patent: 6183746 (2001-02-01), Urban et al.
patent: 6783763 (2004-08-01), Choppin et al.
patent: 0344940 (1989-12-01), None
patent: 0 594 613 (1997-05-01), None
patent: WO 87/01375 (1987-03-01), None
patent: WO 91/18294 (1991-11-01), None
patent: WO 99/10744 (1999-03-01), None
Park et al.,Human papillomavirus type 16 E6, E7, and L1 and type 18 E7 proteins produced by recombinant baculoviruses,Journal of Virological Methods, 45:303-318, 307, 1993.
Anonymous, Cervical cancer, NIH Consensus Statement Apr. 1-3, 1996; 14(1):1-38.
Arends et al., Aetiology, pathogenesis, and pathology of cervical neoplasia, Journal of Clinical Pathology 1998; 51:96-103.
Birdsong G.C., Automated rescreening of Pap smears: what are the implications?, Diagnostic Cytopathology, 1996; 13:283-8.
Boryslewicz et al., A recombinant vaccina virus encoding human papillomavirus types 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer, Lancet 1996; 347:1523-7.
Bryan et al., Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle, Journal of Med Virology 1997; 53:185-8.
Chee et al., Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins, Gynecology Oncology 1995; 57:226-231.
Clavel et al., DNA-EIA to detect high and low risk HPV genotypes in cervical lesions with E6/E7 primer mediated multiplex PCR, Journal of Clinical Pathology 1998; 51(1):38-43.
Cox et al., Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance, American Journal of Obstetrics and Gynecology 1995; 172:946-54.
Cuzick et al., A systematic review of the role of human papilloma virus (HPV) testing within a crevical screening programme: summary and conclusions, British Journal of Cancer 2000; 85(5): 561-65.
Donnelly et al., Protection against papillomavirus with a polynucleotide vaccine, Journal of Infectious Diseases 1996; 713: 314-20.
Dreau et al., Human papilloma virus in melanoma biopsy specimens and its relation to melanoma progression, Annals of Surgery 2000; 231(5): 664-71.
Ferenczy et al., Diagnostic performance of hybrid capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study, American Journal of Obstetrics and Gynecology 1996; 175(3): 651-6.
Frisch et al., Human papillomavirus-associated carcinomas in Hawaii and the mainland U.S., Cancer 2000; 88: 1464-9.
Fu et al., Human papillomavirus and papillomatosis lesion of female lower genital tract, Infectious Disease Obstetrics and Gynecology 1994; 1: 235-41.
Fu et al., Diagnosis between condyloma acuminatum and pseudocondyloma in lower female genital tract as determined by a PCR-based method, Chinese Journal of Obstetrics and Gynecology 1994; 29(1): 168-88. [in Chinese; English abstract].
Gregoire et al., Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma, Journal of the National Cancer Institute 1995; 87(22): 1705-9.
Hagensee et al., Seroprevalence of human papillomavirus type 16 in pregnant women, Obstetrics and Gynecology 1999; 94(5): 653-8.
Hamsikova et al., Presence of antibodies to seven human papillomavirus type 16 derived peptides in cervical cancer patients and health controls, Journal of Infectious Diseases 1994; 170: 1424-31.
Harlan et al., Cervical cancer screening: who is not screened and why?, American Journal of Public Health 1991; 81: 885-91.
Hayward et al., Who gets screened for cervical and breast cancer? Results from a New National Survey, Archives of Internal Medicine 1988; 148: 1117-81.
Hu YX, Introduction and prospect of application of biogenetic engineering, Guangzhou Medical Journal 1990; 2:8-10. [in Chinese, English title].
Hutchinson et al., Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep™ Processor, American Journal of Clinical Pathology 1994; 101: 215-9.
Jochmus et al., Detection of antibodies to the E4 or E7 proteins of human papillomaviruses (HPV) in human sera by western blot analysis: type specific reaction of anti-HPV 16 antibodies, Molecular and Cellular Probes 1992; 6: 319-25
Kochel et al., Antibodies to human papillomavirus type-16 in human sera as revealed by the use of prokaryotically expressed viral gene products, Virology 1991; 182: 644-54.
Konya et al., Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein, Journal of General Virology 1997; 78: 2615-20.
Lorincz et al., Human papillomavirus infection of the cervix: relative risk associations of 16 common anogenital types, Obstetrics and Gynecology 1992; 79: 328-37.
Lowy et al., Papillomaviruses: prophylactic vaccine prospects, Biochimica et Biophysica Acta 1998; 1423: M1-8.
Mellin et al., Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival, International Journal of Cancer (Pred. Oncol.) 2000; 89: 300-4.
Meschede et al., Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer, Journal of Clinical Microbiology 1998; 36(2): 475-80.
Muller et al., Antibodies to the E4, E6 and E7 proteins of human papillomavirus (HPV) type 16 in patients with HPV-associated disease and in the normal population, Journal of Investigative Dermatology 1995; 104: 138-41.
Nobbenhuis et al., Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study, Lancet 1999; 354: 20-5.
Petter et al., Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women, Journal of General Virology 2000; 81: 701-8.
Pirog et al., Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma, American Journal of Pathology 2000; 157(4): 1055-62.
Rice et al., High risk genital papillomavirus infections are spread vertically, Review of Medical Virology 1999; 9: 15-21.
Schiffman MH, Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia, Journal of the National Cancer Institute 1992; 84(6): 394-8.
Silins et al., Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis, Journal of General Virology 1999; 80: 2931-6.
Slawson et al., Follow up papanicolau smear for cervical atypia: are we missing significant disease? A HARNET study, Journal of Family practice 1993; 36(3): 289-93.
Soini et al., Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung
Hu Yao Xiong
Rosenfeld Mark J.
Hu Yao Xiong
Pate Pierce & Baird P.C.
Salimi Ali R.
LandOfFree
Peptides from the E2, E6, and E7 proteins of human papilloma... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides from the E2, E6, and E7 proteins of human papilloma..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides from the E2, E6, and E7 proteins of human papilloma... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3450766